Načítá se...
Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia (CML). Imatinib at a dose of 400 mg/day is considered the standard treatment for all newly diagnosed chronic phase CML. Follow-up on the pivotal International Randomized Study of I...
Uloženo v:
| Vydáno v: | Hematol Oncol Clin North Am |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428141/ https://ncbi.nlm.nih.gov/pubmed/22054730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2011.09.004 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|